Avzivi? (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi? is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI ? (格樂立 ? ), a biosimilar to Humira ? (adalimumab), is now available in China. QLETLI ? (格樂立 ? ), the first adalimumab biosimilar approved by the Chi...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a Phase I clinical study to compare the phar...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved QLETLI ? (格樂立 ? ) for all eligible indications of the reference product, Humira ? (adalimumab)...
